Emcure Pharmaceuticals Ltd (EMCURE) - Total Liabilities
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) has total liabilities worth Rs46.36 Billion INR (≈ $501.35 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Emcure Pharmaceuticals Ltd - Total Liabilities Trend (2022–2026)
This chart illustrates how Emcure Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See EMCURE net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Emcure Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Emcure Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hisense Kelon Electrical Holdings Co Ltd
SHE:000921
|
China | CN¥51.29 Billion |
|
Orla Mining Ltd
TO:OLA
|
Canada | CA$1.95 Billion |
|
COPT Defense Properties
NYSE:CDP
|
USA | $3.11 Billion |
|
F&G Annuities & Life Inc.
NYSE:FG
|
USA | $96.28 Billion |
|
Shenzhen Everbest Machinery Indus
SHE:002980
|
China | CN¥371.92 Million |
|
Appfolio Inc
NASDAQ:APPF
|
USA | $110.33 Million |
|
Zhengzhou Coal Mining Machinery Group Co Ltd
SHG:601717
|
China | CN¥24.09 Billion |
|
LG Display Co. Ltd
F:LGA
|
Germany | €19.08 Trillion |
Liability Composition Analysis (2022–2026)
This chart breaks down Emcure Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EMCURE market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Emcure Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Emcure Pharmaceuticals Ltd (2022–2026)
The table below shows the annual total liabilities of Emcure Pharmaceuticals Ltd from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs46.36 Billion ≈ $501.35 Million |
+29.09% |
| 2025-03-31 | Rs35.91 Billion ≈ $388.37 Million |
-23.34% |
| 2024-03-31 | Rs46.84 Billion ≈ $506.60 Million |
+16.44% |
| 2023-03-31 | Rs40.23 Billion ≈ $435.06 Million |
+1.86% |
| 2022-03-31 | Rs39.49 Billion ≈ $427.10 Million |
-- |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more